open access

Vol 61, No 1 (2010)
Original papers
Published online: 2010-03-04
Submitted: 2013-02-15
Get Citation

The serum profile of adipokines in overweight patients with metabolic syndrome

Maria Gnacińska, Sylwia Małgorzewicz, Wiesława Łysiak-Szydłowska, Krzysztof Sworczak
Endokrynologia Polska 2010;61(1):36-41.

open access

Vol 61, No 1 (2010)
Original papers
Published online: 2010-03-04
Submitted: 2013-02-15

Abstract


Introduction: Obesity is a disease that brings several complications and increases the risk of other diseases like metabolic syndrome, diabetes mellitus type 2, or coronary heart disease. Disturbances in secretion of adipokines caused by obesity have an influence on the development of metabolic complications. The aim of this study was an investigation of adipokines profile in overweight or obese people with metabolic syndrome in comparison to overweight/obese patients without metabolic syndrome.
Material and methods: The studied groups consisted of 38 obese or overweight patients without metabolic syndrome (nonMS) and 17 with recognized metabolic syndrome (MS), according to International Diabetes Federation (IDF) criteria. All individuals underwent anthropometrical and blood-pressure examination as well as biochemical analyses such as: serum concentrations of glucose, insulin, adiponectin, resistin, leptin, TNF-α, IL-6, hs-CRP, total cholesterol, HDL, and triglycerides.
Results: A significantly lower concentration of adiponectin, and a higher concentration of IL-6, was observed in patients with metabolic syndrome (MS) in comparison to nonMS. Moreover, higher concentrations of hs-CRP and TNF-α were observed in patients with metabolic syndrome.
Conclusions: A decreased concentration of adiponectin in obese people is an early predictor of metabolic syndrome. A low adiponectin level could be a marker of high risk of cardiovascular disease in obese patients.
(Pol J Endocrinol 2010; 61 (1): 36-41)

Abstract


Introduction: Obesity is a disease that brings several complications and increases the risk of other diseases like metabolic syndrome, diabetes mellitus type 2, or coronary heart disease. Disturbances in secretion of adipokines caused by obesity have an influence on the development of metabolic complications. The aim of this study was an investigation of adipokines profile in overweight or obese people with metabolic syndrome in comparison to overweight/obese patients without metabolic syndrome.
Material and methods: The studied groups consisted of 38 obese or overweight patients without metabolic syndrome (nonMS) and 17 with recognized metabolic syndrome (MS), according to International Diabetes Federation (IDF) criteria. All individuals underwent anthropometrical and blood-pressure examination as well as biochemical analyses such as: serum concentrations of glucose, insulin, adiponectin, resistin, leptin, TNF-α, IL-6, hs-CRP, total cholesterol, HDL, and triglycerides.
Results: A significantly lower concentration of adiponectin, and a higher concentration of IL-6, was observed in patients with metabolic syndrome (MS) in comparison to nonMS. Moreover, higher concentrations of hs-CRP and TNF-α were observed in patients with metabolic syndrome.
Conclusions: A decreased concentration of adiponectin in obese people is an early predictor of metabolic syndrome. A low adiponectin level could be a marker of high risk of cardiovascular disease in obese patients.
(Pol J Endocrinol 2010; 61 (1): 36-41)
Get Citation

Keywords

metabolic syndrome; obesity; adipokines

About this article
Title

The serum profile of adipokines in overweight patients with metabolic syndrome

Journal

Endokrynologia Polska

Issue

Vol 61, No 1 (2010)

Pages

36-41

Published online

2010-03-04

Bibliographic record

Endokrynologia Polska 2010;61(1):36-41.

Keywords

metabolic syndrome
obesity
adipokines

Authors

Maria Gnacińska
Sylwia Małgorzewicz
Wiesława Łysiak-Szydłowska
Krzysztof Sworczak

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl